Drugs of Choice for Clostridium difficile Infection
For initial C. difficile infection, use oral vancomycin 125 mg four times daily for 10 days OR fidaxomicin 200 mg twice daily for 10 days—metronidazole is no longer recommended as first-line therapy when these agents are available. 1
Treatment Algorithm by Clinical Scenario
Initial Episode - Non-Severe Disease
(WBC ≤15,000 cells/mL AND serum creatinine <1.5 mg/dL)
Preferred options:
- Fidaxomicin 200 mg twice daily for 10 days (strong recommendation, high quality evidence) 2, 1
- Vancomycin 125 mg four times daily for 10 days (acceptable alternative) 2, 1
Only if vancomycin/fidaxomicin unavailable:
- Metronidazole 500 mg three times daily for 10-14 days (weak recommendation) 1
- Critical caveat: Avoid repeated or prolonged metronidazole courses due to cumulative and potentially irreversible neurotoxicity 2
Initial Episode - Severe Disease
(WBC ≥15,000 cells/mL OR serum creatinine >1.5 mg/dL)
Same regimens as non-severe:
- Vancomycin 125 mg four times daily for 10 days OR
- Fidaxomicin 200 mg twice daily for 10 days 2
Do NOT use metronidazole for severe disease 1
Fulminant CDI
(Hypotension/shock, ileus, or megacolon)
Aggressive multi-route therapy required:
- Vancomycin 500 mg four times daily by mouth or nasogastric tube
- PLUS IV metronidazole 500 mg every 8 hours (particularly crucial if ileus present)
- If ileus: Add rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as retention enema 2
This represents a strong recommendation with moderate quality evidence for oral vancomycin and IV metronidazole 2.
First Recurrence
Preferred approach:
- Fidaxomicin 200 mg twice daily for 10 days (can also use extended regimen: twice daily for 5 days, then once every other day for 20 days) 1
Alternative options:
- Vancomycin tapered and pulsed regimen (e.g., 125 mg four times daily for 10-14 days, then twice daily for 7 days, once daily for 7 days, then every 2-3 days for 2-8 weeks) 2, 1
- Standard vancomycin 125 mg four times daily for 10 days if metronidazole was used initially 2
Adjunctive therapy to consider:
- Bezlotoxumab 10 mg/kg IV once during antibiotic administration reduces recurrence risk 1
Second or Subsequent Recurrence
Multiple effective options:
- Fidaxomicin 200 mg twice daily for 10 days (or extended regimen)
- Vancomycin tapered and pulsed regimen
- Vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days
- Fecal microbiota transplantation (strong recommendation after ≥2 recurrences/3 total episodes) 2, 1
Adjunctive bezlotoxumab should be strongly considered 1
Key Guideline Evolution
The 2021 IDSA/SHEA focused update 1 represents the most current guidance and made critical changes from the 2018 guidelines 2:
- Fidaxomicin now preferred over vancomycin for initial episodes (when resources permit)
- Metronidazole relegated to last-line status only for non-severe CDI when other agents unavailable
- Bezlotoxumab formally incorporated as adjunctive therapy for recurrence prevention
- Extended fidaxomicin regimens now included as treatment option
The 2021 European guidelines 3 similarly emphasize that metronidazole is no longer recommended when fidaxomicin or vancomycin are available, and place greater emphasis on recurrence risk rather than disease severity alone in determining treatment strategy.
Common Pitfalls to Avoid
Do not use metronidazole as first-line therapy when vancomycin or fidaxomicin are accessible—this represents outdated practice that increases treatment failure and recurrence rates 1, 3, 4
Do not use IV vancomycin—it does not achieve adequate colonic concentrations. Oral or rectal routes are required 2
Do not delay treatment in fulminant cases—empiric therapy should begin immediately without waiting for laboratory confirmation 2
Do not forget to discontinue the inciting antibiotic as soon as possible, as this significantly influences recurrence risk 2
Consider treatment duration extension to 14 days for patients with delayed response, particularly those treated with metronidazole 2
Practical Implementation Considerations
Real-world data from Medicare patients showed that after the 2017 guideline update, metronidazole use decreased significantly (from 81% to 54% for initial CDI), while vancomycin use increased substantially 5. However, fidaxomicin adoption remained low despite superior sustained response rates—13.5% higher for initial CDI and 30% higher for recurrent CDI compared to vancomycin 5. This suggests implementation barriers related to cost and access that clinicians must navigate, though the clinical benefits of fidaxomicin are clear when available.